{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:23:14Z","timestamp":1773048194277,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Research Centre Egypt"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Rett syndrome (RTT) is a rare, life-threatening, genetic neurodevelopmental disorder. Treatment in RTT encounters many challenges. Trofinetide, a modified amino-terminal tripeptide of insulin-like growth factor 1, has demonstrated clinically promising results in RTT. In this study, trofinetide efficacy and safety in RTT are systematically reviewed and meta-analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic search of five electronic databases was conducted until January 2024. Review Manager 5.4 software was used for the analysis. The analysis was based on a weighted mean difference and standard error with a confidence interval (CI) of 95%, and a statistically significant <jats:italic>P<\/jats:italic>-value was considered if it was\u2009&lt;\u20090.05. The study was registered on PROSPERO with registration number CRD42024499849. Quality of evidence was assessed using GRADE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Three randomized controlled trials (RCTs) with 276 patients were included in the analysis. Trofinetide improved both caregiver outcomes and clinical scales by improving the Rett Syndrome Behavior Questionnaire (RSBQ) (mean difference (MD):\u2009\u2212\u20093.46 points, 95% CI:\u2009\u2212\u20095.63 to\u2009\u2212\u20091.27, <jats:italic>P<\/jats:italic>\u2009=\u20090.0002) and Clinical Global Impression Scale\u2013Improvement (CGI-I) (MD:\u2009\u2212\u20090.35, 95% CI:\u2009\u2212\u20090.51 to\u2009\u2212\u20090.18, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001), respectively. However, trofinetide neither improved the Caregiver Top 3 Concerns Visual Analog Scale nor the Rett Motor Behavioral Assessment. Regarding safety, trofinetide was significantly associated with vomiting compared to placebo (odds ratio (OR): 3.17, 95% CI: 1.57 to 6.43, <jats:italic>P<\/jats:italic>\u2009=\u20090.001). After solving heterogeneity, results showed a statistically significant incidence of diarrhea in the trofinetide (200\u00a0mg) group compared to placebo (OR: 18.51, 95% CI: 9.30 to 36.84, <jats:italic>P<\/jats:italic>\u2009\u2264\u20090.00001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Trofinetide demonstrated statistically significant improvements in CGI-I and RSBQ in pediatrics and adult patients with Rett. Side effects are limited to vomiting and diarrhea. Although diarrhea yielded an insignificant result in our analysis, it emerged as a cause for treatment discontinuation in the participating trials, and a statistically significant risk for diarrhea emerged when excluding the study using a lower dose of the drug, hence causing heterogeneity, in the\u00a0meta-analysis. Given the diverse genetic landscape of RTT, future RCTs investigating correlations between RTT genotype and phenotypic improvements by trofinetide will be beneficial. RCTs encompassing male patients with larger and longer cohorts are recommended.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s12916-024-03506-9","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T02:01:31Z","timestamp":1721268091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Is trofinetide a future treatment for Rett syndrome? A comprehensive systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"22","author":[{"given":"Hazem E.","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeyad","family":"Bady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed E.","family":"Haseeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heba","family":"Aboeldahab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wessam E.","family":"Sharaf-Eldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7840-0002","authenticated-orcid":false,"given":"Maha S.","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"3506_CR1","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.2147\/NDT.S371483","volume":"18","author":"BE Collins","year":"2022","unstructured":"Collins BE, Neul JL. Rett syndrome and MECP2 duplication syndrome: disorders of mecp2 dosage. Neuropsychiatr Dis Treat. 2022;18:2813\u201335.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3506_CR2","doi-asserted-by":"publisher","first-page":"620859","DOI":"10.3389\/fgene.2021.620859","volume":"12","author":"KV Good","year":"2021","unstructured":"Good KV, Vincent JB, Ausi\u00f3 J. Mecp2: the genetic driver of rett syndrome epigenetics. Front Genet. 2021;12:620859.","journal-title":"Front Genet"},{"key":"3506_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10354-016-0491-9","volume":"166","author":"AK Percy","year":"2016","unstructured":"Percy AK. Progress in Rett syndrome: from discovery to clinical trials. Wien Med Wochenschr. 2016;166:325\u201332.","journal-title":"Wien Med Wochenschr"},{"key":"3506_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13643-023-02169-6","volume":"12","author":"U Petriti","year":"2023","unstructured":"Petriti U, Dudman DC, Scosyrev E, Lopez-Leon S. Global prevalence of Rett syndrome: systematic review and meta-analysis. Syst Rev. 2023;12:5.","journal-title":"Syst Rev"},{"key":"3506_CR5","unstructured":"What are the treatments for Rett syndrome? | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development. Available from: https:\/\/www.nichd.nih.gov\/health\/topics\/rett\/conditioninfo\/treatments."},{"key":"3506_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/ana.410350415","volume":"35","author":"AK Percy","year":"1994","unstructured":"Percy AK, Glaze DG, Schultz RJ, Zoghbi HY, Williamson D, Frost JD, et al. Rett syndrome: controlled study of an oral opiate antagonist, naltrexone. Ann Neurol. 1994;35:464\u201370.","journal-title":"Ann Neurol"},{"key":"3506_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/0883073808327827","volume":"24","author":"DG Glaze","year":"2009","unstructured":"Glaze DG, Percy AK, Motil KJ, Lane JB, Isaacs JS, Schultz RJ, et al. A study of the treatment of rett syndrome with folate and betaine. J Child Neurol. 2009;24:551\u20136.","journal-title":"J Child Neurol"},{"key":"3506_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.tips.2019.02.007","volume":"40","author":"RG Gogliotti","year":"2019","unstructured":"Gogliotti RG, Niswender CM. A coordinated attack: rett syndrome therapeutic development. Trends Pharmacol Sci. 2019;40:233\u20136.","journal-title":"Trends Pharmacol Sci"},{"key":"3506_CR9","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1073\/pnas.0812394106","volume":"106","author":"D Tropea","year":"2009","unstructured":"Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, Fu DD, et al. Partial reversal of rett syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci USA. 2009;106:2029\u201334.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3506_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.npep.2004.11.001","volume":"39","author":"AM Baker","year":"2005","unstructured":"Baker AM, Batchelor DC, Thomas GB, Wen JY, Rafiee M, Lin H, et al. Central penetration and stability of N-terminal tripeptide of insulin-like growth factor-I, glycine-proline-glutamate in adult rat. Neuropeptides. 2005;39:81\u20137.","journal-title":"Neuropeptides"},{"key":"3506_CR11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ab.2003.08.032","volume":"323","author":"DC Batchelor","year":"2003","unstructured":"Batchelor DC, Lin H, Wen JY, Keven C, Van Zijl PL, Breier BH, et al. Pharmacokinetics of glycine-proline-glutamate, the N-terminal tripeptide of insulin-like growth factor-1, in rats. Anal Biochem. 2003;323:156\u201363.","journal-title":"Anal Biochem"},{"key":"3506_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jns.2008.12.003","volume":"278","author":"MJ Bickerdike","year":"2009","unstructured":"Bickerdike MJ, Thomas GB, Batchelor DC, Sirimanne ES, Leong W, Lin H, et al. NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke. J Neurol Sci. 2009;278:85\u201390.","journal-title":"J Neurol Sci"},{"key":"3506_CR13","first-page":"1142","volume":"329","author":"E Harris","year":"2023","unstructured":"Harris E. Trofinetide receives FDA approval as first drug for rett syndrome. JAMA. 2023;329:1142.","journal-title":"JAMA"},{"key":"3506_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1089\/neu.2008.0629","volume":"26","author":"X-CM Lu","year":"2009","unstructured":"Lu X-CM, Chen R-W, Yao C, Wei H, Yang X, Liao Z, et al. NNZ-2566, a glypromate analog, improves functional recovery and attenuates apoptosis and inflammation in a rat model of penetrating ballistic-type brain injury. J Neurotrauma. 2009;26:141\u201354.","journal-title":"J Neurotrauma"},{"key":"3506_CR15","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1038\/jcbfm.2009.109","volume":"29","author":"XCM Lu","year":"2009","unstructured":"Lu XCM, Si Y, Williams AJ, Hartings JA, Gryder D, Tortella FC. NNZ-2566, a glypromate analog, attenuates brain ischemia-induced non-convulsive seizures in rats. J Cereb Blood Flow Metab. 2009;29:1924\u201332.","journal-title":"J Cereb Blood Flow Metab"},{"key":"3506_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1742-2094-6-19","volume":"6","author":"HH Wei","year":"2009","unstructured":"Wei HH, Lu X-CM, Shear DA, Waghray A, Yao C, Tortella FC, et al. NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats. J Neuroinflammation. 2009;6:19.","journal-title":"J Neuroinflammation"},{"key":"3506_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.5582\/irdr.2023.01060","volume":"12","author":"A Singh","year":"2023","unstructured":"Singh A, Balasundaram MK, Gupta D. Trofinetide in Rett syndrome: a brief review of safety and efficacy. Intractable Rare Dis Res. 2023;12:262\u20136.","journal-title":"Intractable Rare Dis Res"},{"key":"3506_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.pediatrneurol.2017.07.002","volume":"76","author":"DG Glaze","year":"2017","unstructured":"Glaze DG, Neul JL, Percy A, Feyma T, Beisang A, Yaroshinsky A, et al. A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome. Pediatr Neurol. 2017;76:37\u201346.","journal-title":"Pediatr Neurol"},{"key":"3506_CR19","doi-asserted-by":"publisher","first-page":"e1912","DOI":"10.1212\/WNL.0000000000007316","volume":"92","author":"DG Glaze","year":"2019","unstructured":"Glaze DG, Neul JL, Kaufmann WE, Berry-Kravis E, Condon S, Stoms G, et al. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology. 2019;92:e1912\u201325.","journal-title":"Neurology"},{"key":"3506_CR20","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","volume":"29","author":"JL Neul","year":"2023","unstructured":"Neul JL, Percy AK, Benke TA, Berry-Kravis EM, Glaze DG, Marsh ED, et al. Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study. Nat Med. 2023;29:1468\u201375.","journal-title":"Nat Med"},{"key":"3506_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.pediatrneurol.2023.11.005","volume":"152","author":"JL Neul","year":"2024","unstructured":"Neul JL, Percy AK, Benke TA, Berry-Kravis EM, Glaze DG, Peters SU, et al. Trofinetide treatment demonstrates a benefit over placebo for the ability to communicate in rett syndrome. Pediatr Neurol. 2024;152:63\u201372.","journal-title":"Pediatr Neurol"},{"key":"3506_CR22","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1007\/s12325-024-02796-y","volume":"41","author":"M Darwish","year":"2024","unstructured":"Darwish M, Passarell J, Youakim JM, Bradley H, Bishop KM. Exposure-response efficacy modeling to support trofinetide dosing in individuals with Rett syndrome. Adv Ther. 2024;41:1462\u201380.","journal-title":"Adv Ther"},{"key":"3506_CR23","doi-asserted-by":"crossref","unstructured":"Percy AK, Neul JL, Benke TA, Berry-Kravis EM, Glaze DG, Marsh ED, et al. Trofinetide for the treatment of Rett Syndrome: results from the open-label extension lilac study. Med. 2024:j.medj.2024.05.018.","DOI":"10.1016\/j.medj.2024.05.018"},{"key":"3506_CR24","doi-asserted-by":"publisher","first-page":"1341746","DOI":"10.3389\/fphar.2023.1341746","volume":"14","author":"M Kennedy","year":"2023","unstructured":"Kennedy M, Glass L, Glaze DG, Kaminsky S, Percy AK, Neul JL, et al. Development of trofinetide for the treatment of Rett syndrome: from bench to bedside. Front Pharmacol. 2023;14:1341746.","journal-title":"Front Pharmacol"},{"key":"3506_CR25","doi-asserted-by":"publisher","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65\u201394.","journal-title":"Ann Intern Med"},{"key":"3506_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.","journal-title":"Syst Rev"},{"key":"3506_CR27","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1177\/0883073815579707","volume":"30","author":"JL Neul","year":"2015","unstructured":"Neul JL, Glaze DG, Percy AK, Feyma T, Beisang A, Dinh T, et al. Improving treatment trial outcomes for Rett syndrome: the development of rett-specific anchors for the clinical global impression scale. J Child Neurol. 2015;30:1743\u20138.","journal-title":"J Child Neurol"},{"key":"3506_CR28","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"3506_CR29","unstructured":"The Cochrane Collaboration. Review Manager Web (RevMan Web). Version 5.4. The Cochrane Collaboration; 2021. Available from: https:\/\/revman.cochrane.org\/."},{"key":"3506_CR30","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"3506_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jclinepi.2019.12.020","volume":"122","author":"HJ Sch\u00fcnemann","year":"2020","unstructured":"Sch\u00fcnemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. J Clin Epidemiol. 2020;122:129\u201341.","journal-title":"J Clin Epidemiol."},{"key":"3506_CR32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jclinepi.2019.12.021","volume":"122","author":"HJ Sch\u00fcnemann","year":"2020","unstructured":"Sch\u00fcnemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. J Clin Epidemiol. 2020;122:142\u201352.","journal-title":"J Clin Epidemiol."},{"key":"3506_CR33","unstructured":"GRADEpro. Available from: https:\/\/www.gradepro.org\/.\u00a0Accessed 17 Apr\u00a02024."},{"key":"3506_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s11689-015-9127-4","volume":"7","author":"KV Barnes","year":"2015","unstructured":"Barnes KV, Coughlin FR, O\u2019Leary HM, Bruck N, Bazin GA, Beinecke EB, et al. Anxiety-like behavior in Rett syndrome: characteristics and assessment by anxiety scales. J Neurodev Disord. 2015;7:30.","journal-title":"J Neurodev Disord"},{"key":"3506_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s11689-015-9104-y","volume":"7","author":"R Cianfaglione","year":"2015","unstructured":"Cianfaglione R, Clarke A, Kerr M, Hastings RP, Oliver C, Moss J, et al. A national survey of Rett syndrome: behavioural characteristics. J Neurodev Disord. 2015;7:11.","journal-title":"J Neurodev Disord"},{"key":"3506_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ajmg.b.30270","volume":"141B","author":"L Robertson","year":"2006","unstructured":"Robertson L, Hall SE, Jacoby P, Ellaway C, de Klerk N, Leonard H. The association between behavior and genotype in rett syndrome using the australian rett syndrome database. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:177\u201383.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"3506_CR37","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/j.1365-2753.2007.00921.x","volume":"14","author":"M Berk","year":"2008","unstructured":"Berk M, Ng F, Dodd S, Callaly T, Campbell S, Bernardo M, et al. The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use. J Eval Clin Pract. 2008;14:979\u201383.","journal-title":"J Eval Clin Pract"},{"key":"3506_CR38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.comppsych.2008.08.005","volume":"50","author":"J Busner","year":"2009","unstructured":"Busner J, Targum SD, Miller DS. The Clinical Global Impressions scale: errors in understanding and use. Compr Psychiatry. 2009;50:257\u201362.","journal-title":"Compr Psychiatry"},{"key":"3506_CR39","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/21678707.2016.1229181","volume":"4","author":"WE Kaufmann","year":"2016","unstructured":"Kaufmann WE, Stallworth JL, Everman DB, Skinner SA. Neurobiologically-based treatments in Rett syndrome: opportunities and challenges. Expert Opin Orphan Drugs. 2016;4:1043\u201355.","journal-title":"Expert Opin Orphan Drugs"},{"key":"3506_CR40","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/DBP.0b013e31829d1f20","volume":"34","author":"E Berry-Kravis","year":"2013","unstructured":"Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Mitchener A, Urv TK. Outcome measures for clinical trials in fragile X syndrome. J Dev Behav Pediatr. 2013;34:508\u201322.","journal-title":"J Dev Behav Pediatr"},{"key":"3506_CR41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s11689-017-9193-x","volume":"9","author":"DB Budimirovic","year":"2017","unstructured":"Budimirovic DB, Berry-Kravis E, Erickson CA, Hall SS, Hessl D, Reiss AL, et al. Updated report on tools to measure outcomes of clinical trials in fragile X syndrome. J Neurodev Disord. 2017;9:14.","journal-title":"J Neurodev Disord"},{"key":"3506_CR42","unstructured":"Cohen J, editor. Statistical power analysis for the behavioral sciences. 2nd ed. 1988."},{"key":"3506_CR43","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s12325-024-02782-4","volume":"41","author":"R Moore","year":"2024","unstructured":"Moore R, Poulsen J, Reardon L, Samples-Morris C, Simmons H, Ramsey KM, et al. Managing gastrointestinal symptoms resulting from treatment with trofinetide for rett syndrome: caregiver and nurse perspectives. Adv Ther. 2024;41:1305\u201317.","journal-title":"Adv Ther"},{"key":"3506_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21678707.2023.2217328","volume":"11","author":"ED Marsh","year":"2023","unstructured":"Marsh ED, Beisang A, Buie T, Benke TA, Gaucher B, Motil KJ. Recommendations for the management of diarrhea with trofinetide use in Rett syndrome. Expert Opin Orphan Drugs. 2023;11:1\u20138.","journal-title":"Expert Opin Orphan Drugs"},{"key":"3506_CR45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.pediatrneurol.2020.04.019","volume":"110","author":"E Berry-Kravis","year":"2020","unstructured":"Berry-Kravis E, Horrigan JP, Tartaglia N, Hagerman R, Kolevzon A, Erickson CA, et al. A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of fragile X syndrome. Pediatr Neurol. 2020;110:30\u201341.","journal-title":"Pediatr Neurol"},{"key":"3506_CR46","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/MPG.0b013e31824b6159","volume":"55","author":"KJ Motil","year":"2012","unstructured":"Motil KJ, Caeg E, Barrish JO, Geerts S, Lane JB, Percy AK, et al. Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome. J Pediatr Gastroenterol Nutr. 2012;55:292\u20138.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"3506_CR47","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/MPG.0000000000000200","volume":"58","author":"G Baikie","year":"2014","unstructured":"Baikie G, Ravikumara M, Downs J, Naseem N, Wong K, Percy A, et al. Gastrointestinal dysmotility in Rett syndrome. J Pediatr Gastroenterol Nutr. 2014;58:237\u201344.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"3506_CR48","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2174\/15748847113086660069","volume":"8","author":"CA Chapleau","year":"2013","unstructured":"Chapleau CA, Lane J, Pozzo-Miller L, Percy AK. Evaluation of current pharmacological treatment options in the management of Rett syndrome: from the present to future therapeutic alternatives. Curr Clin Pharmacol. 2013;8:358\u201369.","journal-title":"Curr Clin Pharmacol"},{"key":"3506_CR49","unstructured":"Treatment and Symptom Management for Rett Syndrome. Available from: https:\/\/www.ajmc.com\/view\/treatment-and-symptom-management-for-rett-syndrome.\u00a0Accessed 5 Feb\u00a02024."},{"key":"3506_CR50","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40261-022-01156-4","volume":"42","author":"M Darwish","year":"2022","unstructured":"Darwish M, Youakim JM, Harlick J, DeKarske D, Stankovic S. A phase 1, open-label study to evaluate the effects of food and evening dosing on the pharmacokinetics of oral trofinetide in healthy adult subjects. Clin Drug Investig. 2022;42:513\u201324.","journal-title":"Clin Drug Investig"},{"key":"3506_CR51","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/ajmg.a.34418","volume":"158A","author":"NSJ Halbach","year":"2012","unstructured":"Halbach NSJ, Smeets EEJ, van den Braak N, van Roozendaal KEP, Blok RMJ, Schrander-Stumpel CTRM, et al. Genotype-phenotype relationships as prognosticators in Rett syndrome should be handled with care in clinical practice. Am J Med Genet A. 2012;158A:340\u201350.","journal-title":"Am J Med Genet A"},{"key":"3506_CR52","doi-asserted-by":"publisher","first-page":"e12739","DOI":"10.1111\/gbb.12739","volume":"21","author":"BE Collins","year":"2022","unstructured":"Collins BE, Merritt JK, Erickson KR, Neul JL. Safety and efficacy of genetic MECP2 supplementation in the R294X mouse model of Rett syndrome. Genes Brain Behav. 2022;21:e12739.","journal-title":"Genes Brain Behav"},{"key":"3506_CR53","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1212\/01.wnl.0000291011.54508.aa","volume":"70","author":"JL Neul","year":"2008","unstructured":"Neul JL, Fang P, Barrish J, Lane J, Caeg EB, Smith EO, et al. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology. 2008;70:1313\u201321.","journal-title":"Neurology"},{"key":"3506_CR54","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.18632\/aging.101514","volume":"10","author":"L Pauwels","year":"2018","unstructured":"Pauwels L, Chalavi S, Swinnen SP. Aging and brain plasticity. Aging (Albany NY). 2018;10:1789\u201390.","journal-title":"Aging (Albany NY)"},{"key":"3506_CR55","doi-asserted-by":"publisher","first-page":"109","DOI":"10.31887\/DCNS.2013.15.1\/dpark","volume":"15","author":"DC Park","year":"2013","unstructured":"Park DC, Bischof GN. The aging mind: neuroplasticity in response to cognitive training. Dialogues Clin Neurosci. 2013;15:109\u201319.","journal-title":"Dialogues Clin Neurosci"},{"key":"3506_CR56","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s11065-009-9119-9","volume":"19","author":"C Lustig","year":"2009","unstructured":"Lustig C, Shah P, Seidler R, Reuter-Lorenz PA. Aging, training, and the brain: a review and future directions. Neuropsychol Rev. 2009;19:504\u201322.","journal-title":"Neuropsychol Rev"},{"key":"3506_CR57","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ajmg.b.32707","volume":"180","author":"JL Neul","year":"2019","unstructured":"Neul JL, Benke TA, Marsh ED, Skinner SA, Merritt J, Lieberman DN, et al. The array of clinical phenotypes of males with mutations in Methyl-CpG binding protein 2. Am J Med Genet B Neuropsychiatr Genet. 2019;180:55\u201367.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"3506_CR58","volume-title":"GeneReviews(\u00ae)","author":"H Van Esch","year":"1993","unstructured":"Van Esch H, et al. MECP2 duplication syndrome. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJ, et al., editors. GeneReviews(\u00ae). Seattle: University of Washington, Seattle; 1993."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03506-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-024-03506-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03506-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T03:36:49Z","timestamp":1721273809000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-024-03506-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3506"],"URL":"https:\/\/doi.org\/10.1186\/s12916-024-03506-9","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]},"assertion":[{"value":"10 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"299"}}